Home 2020-03-27T11:33:09-06:00


The American Society of Ketamine Physicians advocates that ketamine therapy is an essential service that cannot be interrupted during this crisis.

     “Our patients who suffer from severe depression and suicidality do not suddenly get better just because there is a pandemic. In fact, they are likely to struggle more. Continuing to offer treatment to high risks populations significantly alleviates the additional strain that would otherwise be placed on emergency rooms and urgent care settings,” says Sandhya Prashad, MD, Board Member and Secretary for ASKP. 

We are listening to our members and responding to the COVID-19 crisis. Please go to our COVID-19 webpage.  ASKP’s recent webinar, COVID-19: Providing Quality Care and Safe Practices from ASKP, can be found on this page.

Ketamine Therapy Essential Service During COVID-19 Pandemic

It goes without saying that COVID-19 is on the minds of nearly every American. The societal and economic disruption is almost without precedent. As government officials and clinicians wrestle with issues of how to protect…read more

What is ASKP?

The American Society of Ketamine Physicians is a group of professionals dedicated to the safe clinical use of ketamine for mental health disorders and pain conditions.

ASKP is officially open for membership.

2020 ASKP Annual Meeting

Conference runs October 15th – 17th 

Detroit, Michigan

Click here to register!

The mission of the American Society of Ketamine Physicians

  • to advocate for the safe and effective use of ketamine in the treatment of mental illness and pain disorder

  • to promote high scientific, ethical, and professional standards among physicians providing ketamine therapy for mental illness and pain disorders;

  • to maximize quality of care by furthering knowledge, collaboration, and the exchange of ideas and research in the use of ketamine and other psychotropic medications for the treatment of mental illness and pain disorders.

  • to expand access to ketamine therapy nationwide;

Basics of Administration

All of the providers in our group ascribe to the same basic tenets of safety when administering Ketamine for Non-Anesthetic Indications (KNAI).

1. ASKP serves as a forum to discuss the use of therapeutic Ketamine for Non-Anesthetic Indications (KNAI). KNAI is fundamentally different than the traditional use of ketamine as an anesthetic.

2. We recognize that therapeutic ketamine is being administered by clinicians through different routes of delivery (IV, IM, IN, PO, etc.). ASKP does not endorse any particular route of delivery however we feel it is important that the combination of delivery and dose do not cross over from KNAI to moderate sedation unless the provider and clinical setting are appropriate for that treatment.

3.  ASKP is not a certifying organization. Membership in ASKP and the presence of the ASKP logo on a practitioner’s website does not imply any endorsement of that practitioner’s quality of care by ASKP.

4. Patients should be screened for and have been found to have a condition that is appropriate for ketamine treatment – examples include Unipolar Major Depression, Bipolar Depression, PTSD, OCD, Fibromyalgia, CRPS and other forms of chronic pain.

5. A full history and physical including psychiatric disorders and substance abuse disorders should be completed in the patient’s chart. The patient’s medications and allergies should also be documented to reduce reasonable risk of medication interaction and side effects.

6. Given the off-label nature of ketamine use for these disorders, appropriate consent should be obtained.

7. Practitioners should have their established protocol easily available to the public. The use of “secret formulations” and “proprietary blends” runs counter to the concept of evidence-based medicine.

8. The patient’s vital signs should be monitored during administration and return to pre-administration values before discharge from the clinic.  An appropriately licensed and qualified medical provider should be present during the administration as well.

9. Patients receiving ketamine therapeutically should not be allowed to drive themselves home from their appointment, or for 12 hours after their infusion.

10. We do not support the use of medically unsupervised parenterally administered ketamine.

Thank you again for your interest in joining our society. Please click below to fill out the application

Join Now
 *Your application is subject to approval. We reserve the right to decline your membership.  Once membership is approved, and payment is accepted, memberships and payments will automatically renewed annually, unless ASKP membership staff is notified in writing.
ASKP Mailing Address:
6565 West Loop, Ste 530
Bellaire, TX 77401-3500

2019/2020 American Society of Ketamine Physicians Officers & Board Members

Questions can be addressed to: info@askp.org

Steven Mandel, MD* – President

Sandhya Prashad, MD* – Secretary

Carl J. Bonnett, MD* – Treasurer

Nykol Bailey Rice, CRNA

Megan Oxley, MD* – Membership Chair

Cindy Van Praag, MD

Patrick Sullivan, DO 

Robert Grant, MD – Interim Vice President

*Founding Board Members


The Society does not endorse any of the products, vendors, providers,documentation, or services referenced in this website. Any mention of products, vendors, providers, documentation, or services is for informational purposes only